Vertex Pharmaceuticals Inc (NASDAQ:VRTX)
| 314.91 Delayed Data As of Mar 31 |  +2.75 / +0.88%Today’s Change | 233.01 Today|||52-Week Range 325.19 | +9.05% Year-to-Date |
Latest VRTX News | Press Releases
Today’s Trading
| Previous close | 312.16 |
| Today’s open | 313.17 |
| Day’s range | 312.18 - 315.39 |
| Volume | 34,486 |
| Average volume (3 months) | 1,322,541 |
| Market cap | $81.0B |
Data as of 4:00pm ET, 03/31/2023
Growth & Valuation
| Earnings growth (last year) | +42.72% |
| Earnings growth (this year) | -4.75% |
| Earnings growth (next 5 years) | +10.50% |
| Revenue growth (last year) | +15.04% |
| P/E ratio | 24.6 |
| Price/Sales | 8.55 |
| Price/Book | 5.82 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ZTSZoetis Inc | +2.20 | +1.34% |
| ---- | ||
| GLAXFGlaxoSmithKline | +0.79 | +4.59% |
| GSKGlaxoSmithKline | +0.31 | +0.88% |
Data as of 4:00pm ET, 03/31/2023
Financials
| Next reporting date | May 3, 2023 |
| EPS forecast (this quarter) | $3.07 |
| Annual revenue (last year) | $8.7B |
| Annual profit (last year) | $3.3B |
| Net profit margin | 37.97% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Boston, Massachusetts |
Forecasts
